Although the mechanism is not yet understood, the use of statins during adjuvant endocrine therapy may prevent the recurrence of estrogen-receptor-positive early breast cancer and reduce cancer-related deaths [43, 44]. This evidence concerns the gene ESR1 and breast carcinoma.